Streetbeat News

Stock Prices

ULTA

Ulta Beauty (NASDAQ:ULTA) has been analyzed by 20 analysts, showing a range of opinions from bullish to bearish. The average 12-month price target has decreased by 9.28% to $460.8. Analysts have adjusted their ratings and price targets, reflecting changing market conditions and company performance. Ulta Beauty's financials show strong revenue growth, net margin, ROE, and ROA, with prudent debt management.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

CAT

Caterpillar (NYSE:CAT) has received mixed analyst ratings over the past three months, with a current average 12-month price target of $349.33, up 2.87% from the previous target. Analysts have adjusted their ratings and price targets in response to market conditions, with some lowering and others raising their expectations. Despite revenue challenges, Caterpillar maintains strong profitability and financial health, though it faces debt management issues.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

RIVN

Rivian Automotive's short interest has decreased by 5.79%, with 16.61% of its shares sold short. This is higher than its peers' average of 6.46%. The decrease in short interest may indicate a shift in market sentiment.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

VKTX

Viking Therapeutics (NASDAQ:VKTX) has significantly outperformed the market over the past 5 years, with an annualized return of 39.42% and an average annual return of 53.7%. A $100 investment in VKTX 5 years ago would now be worth $817.40, highlighting the power of compounded returns.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

GMED

Globus Medical's short interest has decreased by 29.25%, with 4.83 million shares sold short, representing 4.79% of its float. This is higher than its peers' average of 4.44%. The decrease in short interest may indicate a more bullish sentiment.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

HUMA

Humacyte's short interest has decreased by 17.8%, with 12.01 million shares sold short, representing 13.3% of its float. This is lower than its peers' average short interest of 15.20%. A decrease in short interest can indicate a more bullish sentiment.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

HQY

HealthEquity (NASDAQ:HQY) has outperformed the market over the past 10 years with an average annual return of 14.28%, resulting in a $1000 investment growing to $3,772.27. The article highlights the impact of compounded returns over time.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

CDNA

In the last three months, four analysts have rated CareDx (NASDAQ:CDNA) with a bullish outlook. The average 12-month price target has increased by 64.45% to $28.5. Analysts from BTIG, Goldman Sachs, and Craig-Hallum have raised their price targets, reflecting positive sentiment. CareDx, a precision medicine company, has shown a 31.26% revenue growth rate, though it remains below industry averages. The company's financial health is strong, with efficient cost management and a sound debt structure.

Portfolio Pulse from Benzinga Insights

August 19, 2024 | 2:00 pm

ABIO

ARCA Biopharma shares rose following the announcement of a special dividend of $1.59 per share.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 1:59 pm

ALZN

Alzamend Neuro shares have resumed trading after a temporary halt. This development is significant for investors as it may impact the stock's short-term price movement.

Portfolio Pulse from Benzinga Newsdesk

August 19, 2024 | 1:58 pm